Stockscreener 앱 받기
15.91
3.11%
-0.51
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks - Seeking Alpha
SRPT INVESTOR REMINDER: Sarepta Therapeutics, Inc. Stock - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
Sarepta Therapeutics Inc (SRPT) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Sarepta Therapeutics (SRPT) Announces Restructuring and - GlobeNewswire
Amid FDA turmoil Sarepta’s gene therapy worries begin to ease - European Pharmaceutical Review
Untangling Sarepta’s gene therapy fallout and a growing trust deficit - Fierce Pharma
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Roche Slammed With Negative EMA CHMP Opinion for Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
SRPT INVESTOR FRAUD: Sarepta Therapeutics, Inc. Investors are Notified the Company was Sued for Fraud and to Contact BFA Law by August 25 Legal Deadline - Newsfile
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action PendingHagens Berman - PR Newswire
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results - The Globe and Mail
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. LawsuitSRPT - PR Newswire
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky Before August 25, 2025 - ACCESS Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Sarepta Therapeutics (NASDAQ:SRPT) Sees Strong Trading Volume on Analyst Upgrade - Defense World
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
FDA Gives Sarepta Green Light to Restart Shipment of DMD Gene Therapy Elevidys to Patients who are Ambulatory - CGTLive®
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, - GlobeNewswire
SRPT INVESTOR NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors to Contact the Firm before the Imminent August 25 Class Action Deadline - Newsfile
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - ACCESS Newswire
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient - GlobeNewswire
Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdles - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by Barclays to “Equal Weight” Rating - Defense World
FDA’s Prasad Exits Following Political Backlash Over Sarepta - Bloomberg
FDA’s Prasad Exits Following Political Backlash Over Sarepta (3) - Bloomberg Law News
FDA vaccines head, chief medical officer Vinay Prasad departs agency - Seeking Alpha
Sarepta Therapeutics stock price target raised to $19 from $14 at Mizuho - Investing.com
Stocks making the biggest moves midday: Harley-Davidson, Wingstop, Sarepta Therapeutics and more - CNBC
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
Sarepta, other Mass. biotech stocks rise on Prasad’s FDA exit - The Business Journals
Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs - Seeking Alpha
US FDA's top vaccine official Vinay Prasad leaves agency after short stint - Reuters
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy - Fierce Pharma
Sarepta gene therapy deaths highlight tragic rare disease dilemma - Chemistry World
Why SRPT Stock Surged 48%? - timothysykes.com
Sarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at Morgan Stanley - Defense World
Bernstein raises Sarepta Therapeutics stock price target to $18 on Elevidys - Investing.com
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by JPMorgan Chase & Co. to “Neutral” Rating - Defense World
SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - GlobeNewswire
Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings - BioSpace
Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to Equal Weight - Defense World
Sarepta Therapeutics (SRPT) Faces Renewed Scrutiny After ELEVIDYS Linked Safety Events and Legal Challenges - simplywall.st
Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy - Mint
Is Sarepta Therapeutics Inc. forming a reversal patternFree Exit Ready Momentum Stock Watchlist - Newser
BMO Capital Markets Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Sarepta Therapeutics (SRPT) Faces FDA Challenges Amid Executive Departure - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Outperform at Oppenheimer - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given New $15.00 Price Target at Piper Sandler - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright - Defense World
Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use - TipRanks
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade - Defense World
Vinay Prasad is out at FDA, following Sarepta decision and vaccine controversies - Endpoints News
Sarepta soars after FDA says some patients can get Elevidys - The Boston Globe
Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments - Investor's Business Daily
Sarepta Therapeutics, Inc. (SRPT): “You Don’t Court Homicide,” Says Jim Cramer - Yahoo Finance
Sarepta Stock On the Rise Following Resumption of Elevidys Shipments in US - PharmExec
Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault. - MSN
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys - Stocktwits
Market movers: PayPal, Sarepta Therapeutics, UnitedHealth... - Proactive financial news
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers - inkl
0.93%
0.15%
자본화:
|
볼륨(24시간):